Notably, reduction of atherogenic apoB-containing lipoproteins, as an efficient therapeutic approach in HoFH, can be achieved via miR-122, miR-34a and miR-30c mimics, which are known to reduce atherogenic lipoproteins independent of LDLR. Here, APOB is linked to homozygous familial hypercholesterolemia.